



# Blood glucose and epicardial adipose tissue at the hospital admission as possible predictors for COVID-19 severity

G. Guarisco<sup>1</sup> · M. Fasolo<sup>1</sup> · D. Capoccia<sup>1</sup> · G. Morsello<sup>1</sup> · A. Carraro<sup>2</sup> · P. Zuccalà<sup>3</sup> · R. Marocco<sup>3</sup> · C. Del Borgo<sup>3</sup> · G. Pelle<sup>4</sup> · A. Iannarelli<sup>4</sup> · E. Orlando<sup>5</sup> · A. Spagnoli<sup>2</sup> · I. Carbone<sup>5</sup> · M. Lichtner<sup>2,3</sup> · G. Iacobellis<sup>6</sup> · F. Leonetti<sup>1</sup> · the COVID-19 Latina Study Group

Received: 23 June 2021 / Accepted: 20 October 2021 / Published online: 3 November 2021  
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

## Abstract

**Purpose** To study the possible association of CT-derived quantitative epicardial adipose tissue (EAT) and glycemia at the admission, with severe outcomes in patients with COVID-19.

**Methods** Two hundred and twenty-nine patients consecutively hospitalized for COVID-19 from March 1st to June 30th 2020 were studied. Non contrast chest CT scans, to confirm diagnosis of pneumonia, were performed. EAT volume (cm<sup>3</sup>) and attenuation (Hounsfield units) were measured using a CT post-processing software. The primary outcome was acute respiratory distress syndrome (ARDS) or in-hospital death.

**Results** The primary outcome occurred in 56.8% patients. Fasting blood glucose was significantly higher in the group ARDS/death than in the group with better prognosis [114 (98–144) vs. 101 (91–118) mg/dl,  $p = 0.001$ ]. EAT volume was higher in patients with vs without the primary outcome [103 (69.25; 129.75) vs. 78.95 (50.7; 100.25) cm<sup>3</sup>,  $p < 0.001$ ] and it was positively correlated with glycemia, PCR, fibrinogen,  $P/F$  ratio. In the multivariable logistic regression analysis, age and EAT volume were independently associated with ARDS/death. Glycemia and EAT attenuation would appear to be factors involved in ARDS/death with a trend of statistical significance.

**Conclusions** Our findings suggest that both blood glucose and EAT, easily measurable and modifiable targets, could be important predisposing factors for severe Covid-19 complications.

**Keywords** COVID-19 · Epicardial adipose tissue · Hyperglycemia · Visceral fat · Adiposity

---

A list of members and their affiliations appears in the Supplementary Information.

---

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1007/s12020-021-02925-5>.

✉ G. Guarisco  
gloriaguarisco@gmail.com

<sup>1</sup> Diabetes Unit, Department of Medical-Surgical Sciences and Biotechnologies, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy

<sup>2</sup> Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

<sup>3</sup> Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy

## Introduction

Covid-19 is a global pandemic and public health issue of ever-increasing proportions (<https://covid19.who.int/>). Obesity and in particular excess visceral fat are implicated in development of heart and lung complications of Covid-19 due to a chronic inflammatory condition. Adipose tissue has been suggested to play a role as a reservoir for the virus and amplifier of the inflammatory response [1–4].

<sup>4</sup> Department of Diagnostic and Interventional Radiology, Santa Maria Goretti Hospital, Latina, Italy

<sup>5</sup> Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, I.C.O.T. Hospital, Latina, Italy

<sup>6</sup> Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami, Miami, FL, USA

Epicardial adipose tissue (EAT), the visceral fat of the heart, is characterized by a dense macrophage infiltrates and secretion of proinflammatory cytokines, such as interleukin-6 (IL-6), overexpressed in Covid-19 patients with heart and lung diseases [5, 6]. Because its pro inflammatory properties, EAT can contribute to the development of Covid-19 cardiac and pulmonary complications [6–10]. EAT volume and attenuation, a marker of inflammation, can be measured with chest computed tomography (CT) methods, currently used as primary tool for detecting Covid-19 pneumonia [11, 12]. Furthermore, hyperglycemia has been described in more than half of the patients with Covid-19 infection [13]. Although stress-induced hyperglycemia is a physiological response, it may lead to further complications in hospitalized patient with pneumonia, independently of the previous diagnosis of diabetes [14]. To prevent the severity of the disease, our efforts are increasingly focused on identifying the best clinical parameters at the time of admission to predict the risk of complications and improve the stratification of patients to undergo more effective therapies from the earliest stages of the disease [15, 16]. In this study we sought to examine the association of CT-derived quantitative EAT volume and attenuation and metabolic markers at the admission, in particular blood glucose, with worst outcomes (acute respiratory distress syndrome or death) in hospitalized patients with Covid-19.

## Materials and methods

### Study design and population

This is a retrospective study conducted by the Latina Covid-19 Study Group on 229 patients consecutively hospitalized for Covid-19 from March 1st to June 30th, 2020 in Santa Maria Goretti Hospital in Latina, Polo Pontino of Sapienza University of Rome.

All patients who went to the emergency room with symptoms suggestive for Covid-19 (body temperature  $\geq 37.5$  °C, cough, and dyspnea) underwent triage in an out-of-hospital facility where vital signs were detected by a dedicated staff.

The diagnostic protocol included the execution of nasopharyngeal swab RT PCR and chest CT to determine and quantify the presence of interstitial pneumonia.

All patients with confirmed positivity to Sars-CoV2 and with chest CT scan suggestive of interstitial pneumonia, were hospitalized.

Routine laboratory tests were obtained at hospital admission. All patients underwent the same therapy used until June 30th, 2020 (according to internal hospital protocol) and based on methylprednisolone, azithromycin, lopinavir/ritonavir, hydroxychloroquine and enoxaparin.

All subjects with  $P/F$  ratio  $< 200$  underwent therapy with tocilizumab. Every patient received oxygen support with different  $FiO_2$  and different devices depending on respiratory distress degree and subjected to repeated blood gas analysis.

The study was approved by the local institutional review board (IRB), and written informed consent was obtained from all study participants.

### Anthropometric, clinical, and laboratory assessments

The following anthropometric data were extrapolated from the medical records of the subjects included in this analysis and refer to the time of admission: age, gender, height, weight, and BMI.  $P/F$  ratio was determined in all patients by blood gas analysis. Waist circumference was obtained from chest CT scans which included the upper abdomen up to approximately 3 cm above the umbilical line. Among the blood chemistry tests it was possible to collect the following parameters: complete blood count with differential, glycemia, creatinine, total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides, uricaemia, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), Gamma Glutamyl transferase (GGT), Lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), c-reactive protein, ferritin, fibrinogen, and D-dimer. Data from the medical records of 229 hospitalized patients were collected and a database was set up for subsequent analysis.

### CT fat deposition assessment

Non contrast chest CT scans were performed with TC Force Siemens Dual Energy. Isovolumetric, thin slice (1.25 mm) chest CT scan was used for volumetric quantification of EAT, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) by means of advanced CT post-processing software (Intuition; Terarecon). The software made it possible to perform the semi-automatic volumetric segmentation of the EAT. To estimate the EAT volume, the pericardium was manually contoured, by the same operator, and considered as the outer segmentation limit.

EAT density (Hounsfield Unit) was determined by the positioning of a 6 mm ROI (region of interest) at the pulmonary arteries. The Hounsfield Units (HU) scale ranges from  $-1024$  HU to  $3071$  HU. It is defined by the following:  $-1024$  HU is black and represents air (in the lungs).  $0$  HU represents water. Fat is around  $-100$  HU. To estimate the VAT volume, the internal costal limit was manually contoured, also including EAT in the calculation. SAT volume was obtained as the subtraction between total adipose tissue, automatically calculated by the software, and VAT.

## Outcomes and definitions

The composite primary outcome was defined as any degree of acute respiratory distress syndrome (ARDS) or death. ARDS is classified into mild ( $200 \text{ mm} < \text{PaO}_2/\text{FiO}_2 \leq 300$ ), moderate ( $100 \text{ g} < \text{PaO}_2/\text{FiO}_2 \leq 200$ ), and severe ( $\text{PaO}_2/\text{FiO}_2 \leq 100$ ), in according to the 2012 Berlin criteria [17]. P/F was recorded at baseline (P/F baseline) and at the worst clinical condition during hospitalization (P/F nadir).

Diagnosis of type 2 diabetes was defined by a self-reported history of diabetes.

## Statistical analysis

Continuous variables were expressed as mean and standard deviation or median and Interquartile range (IQR) according to their distribution. Categorical variables were recorded as frequencies and percentages. Comparisons between patients with and without the primary outcome were performed using, Mann–Whitney *U*-test, *T*-test or the chi-square test, as appropriate. Kruskal–Wallis test was used to assess differences among groups with different degrees of ARDS and post hoc, *p*-value were adjusted according to Benjamini and Hochberg to account for multiple comparisons.

Spearman's correlation coefficient was used to assess relationship between CT parameters, serum biomarkers, and clinical variables. Multivariable logistic regression analysis was performed to investigate on the relationship between the risk of having ARDS or death and Glycemia, EAT HU, EAT volume, age, and gender. Model selection was performed by stepwise procedure based on the Akaike Information Criterion (AIC).

All tests were two-tailed, and a *p*-value  $< 0.05$  was considered as statistically significant. Analyses were performed using R version 4.0.1 (The R Project for Statistical Computing).

## Results

### Patients characteristics

A total of 229 patients (age 63 [15]; 56.8% male) with laboratory-confirmed Covid-19 who underwent chest CT during their admission were included. The primary outcome (ARDS or in-hospital death) occurred in 130 (56.8%) patients. The remaining patients ( $n = 99$ ; 43.2%) had been discharged alive or otherwise did not develop ARDS during hospitalization at the time of data collection. Mild, moderate, and severe ARDS occurred respectively in 34 (27%), 68 (54%), and 24 (19%) patients out of 126 patients with ARDS. The clinical and laboratory features of patients with and without the primary outcome are reported in Table 1.

Patients with ARDS or died were older than the other group (age respectively 57 [5.47–68] and 66 [55–78];  $p < 0.001$ ). The ratio of men to women in the two groups did not differ significantly: the prevalence of male patients in the group ARDS/death was 40% vs. 47.5% in the comparison group ( $p = 0.319$ ). As regards anthropometric parameters in the two groups, with the available data (115 observations), body weight appeared to be significantly higher in the worst outcome group, while the difference in BMI was close to statistical significance. Waist circumference median value was higher in ARDS/death patients (86 cm vs. 82 cm,  $p = 0.005$ ). The prevalence of diabetes mellitus was 18.2% in patients with better outcome and 36.2% in patients with worse prognosis, with a statistically significant difference ( $p = 0.005$ ). The prevalence of hypertension too was higher in the ARDS/death group ( $p = 0.004$ ), with the available data (104 observations). Fasting blood glucose values were significantly higher in the group ARDS/death than in the group with better prognosis, showing values of 114 (98–144) mg/dl vs. 101 (91–118) mg/dl ( $p = 0.001$ ), respectively. As regards the other nutritional and metabolic parameters, liver function indices (Alanine Aminotransferase—ALT, Aspartate Aminotransferase—AST, and Gamma Glutamyl Transferase—GGT) reached higher values in the worst outcome group, while higher HDL levels appeared to be associated with a better prognosis. Differences in serum inflammatory markers were found between the two groups. Patients with worse outcome showed a reduction of lymphocyte counts and an increase in the percentage of neutrophils. C-reactive protein, ESR, D-Dimer, and fibrinogen were significantly higher in the worst outcome group, as well as LDH concentration.

### Chest CT measurements

The chest CT processing showed a median EAT volume of the whole cohort of  $91.7 \text{ cm}^3$  (57.13–122), a median VAT volume of  $789 \text{ cm}^3$  (412.5–1270.5) and a median VAT/SAT ratio of 0.036 (0.026–0.055) while median EAT attenuation overall was  $-88,78$  ( $-102.83$ ;  $-71.68$ ) HU. EAT volume was higher in patients with versus without the primary outcome ( $103 \text{ cm}^3$  [25–129] vs.  $78.95 \text{ cm}^3$  [7–100],  $p < 0.001$ ). VAT volume was higher in ARSD/death group versus no ARDS/death group ( $867 \text{ cm}^3$  [512–1356] vs.  $578.5 \text{ cm}^3$  [8–1188],  $p = 0.005$ ). The difference in EAT HU and in VAT/SAT between the two groups was not significant (Fig. 1A–C). Depending on the degree of ARDS, median (IQR) EAT volume was  $77.10 \text{ cm}^3$  (51.40–101.00) in the group No ARDS and  $93.40 \text{ cm}^3$  (60.98–119.75),  $99.50 \text{ cm}^3$  (68.30–133.50), and  $121.50 \text{ cm}^3$  (89.75–132.75) in those with mild, moderate, and severe ARDS respectively, with a statistically significant difference among groups ( $p < 0.001$ , Kruskal–Wallis test). The pairwise


**Table 1** Anthropometric, clinical, and laboratory characteristics of patients on admission

	ARDS or death		<i>p</i> value
	No ( <i>N</i> = 99)	Yes ( <i>N</i> = 130)	
<i>Anthropometric and clinical characteristics</i>			
Age, (years)	57 (47–68.5)	66 (55–78.75)	<0.001
Male sex	52 (52.5)	78 (60)	0.319
Weight (kg) (126)	76.5 (65–85), 50	80 (72–90), 76	0.022
Body mass index (kg/m <sup>2</sup> ) (126)	26.23 (23.57–29.41), 50	27.78 (24.58, 30.91), 76	0.05
Systolic blood pressure	122.5 (120–140)	120 (120–140)	0.932
Diastolic blood pressure	80 (70–80)	80 (70–80)	0.862
Diabetes mellitus (%)	18.2	36.2	0.005
Hypertension (%) (104)	27.5	56.3	0.004
Cardiovascular events (%)	10	10.8	0.901
<i>P/F</i> ratio	400 (359.5–457)	298 (218–356)	<0.001
<i>P/F</i> nadir	381 (388–439)	155 (123.25–211.25)	<0.001
<i>Blood biomarkers</i>			
Leukocytes (*10 <sup>3</sup> /μL)	5.810 (4.275–7.708)	5.630 (4.115–7.780)	0.864
Neutrophils (*10 <sup>3</sup> /μL)	3.705 (2.505–5.667)	4.330 (2.345–6.00)	0.485
Lymphocytes (*10 <sup>3</sup> /μL)	1.440 (0.993–1.868)	0.990 (0.735–1.360)	<0.001
Neutrophils (%)	61.83 ± 12.66	70.85 ± 14.83	<0.001
Lymphocytes (%)	26.45 ± 10.26	20.31 ± 10.99	0.002
Hemoglobin (g/dL)	13.51 ± 1.64	13.23 ± 1.93	0.264
Platelets (*10 <sup>3</sup> /μL)	209 (176–259)	197 (153–257)	0.394
Glycemia (mg/dL)	101 (91–118)	114 (98–144)	0.001
Total cholesterol (mg/dL) (73)	165.28 ± 32.45	152.34 ± 36.01	0.116
High-density lipoprotein cholesterol (mg/dL) (73)	36 (25.5–48)	31 (24.5–37)	0.044
Low-density lipoprotein cholesterol (mg/dL) (73)	107.4 ± 28.09	99.59 ± 34.94	0.306
Triglycerides (mg/dL) (73)	95 (68–130)	120 (88.5–136.5)	0.103
Uricemia (mg/dL) (66)	4.7 (3.75–5.62)	4.65 (3.73–6.7)	0.568
Aspartate aminotransferase (AST, U/L)	21 (16.5–26.5)	27 (20–42)	<0.001
Alanine aminotransferase (ALT, U/L)	21 (14.5–29.5)	24 (15.5–40)	0.160
Gamma glutamyl transferase (GGT, U/L) (78)	25.5 (15.75–42.75)	35 (20–57)	0.015
Creatinine (mg/dL)	0.84 (0.73–1.09)	0.95 (0.77–1.27)	0.113
Lactate dehydrogenase (U/L)	198.5 (177.75–246m25)	288.5 (216.25–375.25)	<0.001
Erythrocyte sedimentation rate (ESR) (mm/h)	35 (17.5–50.75)	56 (35–72.5)	0.008
C-reactive protein (mg/dL)	0.67 (0.20–2.69)	4.62 (1.53–13.54)	<0.001
Ferritin (ng/mL) (61)	258 (130–429)	339.5 (171.5–948)	0.113
Fibrinogen	386.5 (318–448.5)	464 (397.5–567)	<0.001
D-dimer (mg/L) (79)	0.42 (0.28–0.99)	0.96 (0.59–1.63)	<0.001
Albumin (40)	3.81 ± 0.46	3.28 ± 0.53	0.002
EAT (cm <sup>3</sup> )	78.95 (51.52–99.95)	103.00 (69.92–128.75)	<0.0001
EAT density (HU)	−87.76 (−100.72–−70.38)	−89.99 (−103.70– −74.73)	0.684
VAT (cm <sup>3</sup> )	578.5 (373.8–1188.8)	867 (512–1356)	0.005
VAT/SAT	0.038 (0.025–0.056)	0.036 (0.026–0.052)	0.5
Waist circumference (cm)	82 (69–92.5)	86 (78–101)	0.005

Data are *n* (%), median (IQR), or mean ± SD, *n* if fewer patients had laboratory results available than the total study population

comparison showed that EAT volume was significantly different between of No ARDS and moderate ARDS groups (*p* = 0,015) and between No ARDS and severe ARDS

groups (*p* = 0.002), (Fig. 1D). Median (IQR) EAT density was −89.62 HU (−100.78 to −70.47) in patients without ARDS, and −87.47 HU (−107.08 to −74.89), −90.00 HU



**Fig. 1** A–C Differences in epicardial adipose tissue volume (A) and attenuation (B) and in VAT/SAT (C) in patients with and without clinical deterioration or death; D–F Differences in epicardial adipose

tissue (D) and attenuation (E) and in VAT/SAT (F) in patients without ARDS, and with increasing degrees of ARDS (mild, moderate, and severe)

(−102.73 to −74.51) and −80–53 HU (−101.73 to −73.88) in patients with mild, moderate and severe ARDS, respectively ( $p = 0.975$ , Kruskal–Wallis test), (Fig. 1E). Median VAT/SAT (IQR) was 0.038 (0.025–0.056) in patients without ARDS, and 0.04 (0.033–0.061), 0.032 (0.024–0.041), and 0.039 (0.026–0.048) in patients with mild, moderate, and severe ARDS, respectively ( $p = 0.109$ , Kruskal–Wallis test), (Fig. 1F).

### Correlation of EAT with clinical, inflammatory, and metabolic variables

Spearman’s rho correlation coefficient between CT parameters, serum biomarkers, and clinical variables are presented in Table 2.

As also showed in Fig. 2 the EAT was positively correlated with glycemia ( $\rho = 0.17$ ,  $p = 0.0002$ ), waist circumference ( $\rho = 0.71$ ,  $p < 0.001$ ) and with inflammatory markers as PCR ( $\rho = 0.30$ ,  $< 0.001$ ), and fibrinogen ( $\rho = 0.16$ ,  $p = 0.032$ ). An inverse correlation was observed between EAT and P/F ratio ( $\rho = -0.24$ ,  $p = 0.0006$ ) and between EAT and P/F nadir ( $\rho = -0.30$ ,  $p < 0.001$ ).

### ARDS/death risk factors in COVID-19 patients

Univariate analysis showed a significant association between ARDS/death and age, glycemia EAT volume and waist circumference. In the multivariable logistic regression

analysis, age (OR 1.025, 95% CI: 1.003–1.049,  $p$ -value = 0.0291) and EAT volume (OR 1.009, 95% CI: 1.002–1.018,  $p$ -value = 0.0207) were independently associated with ARDS onset or death. Glycemia (OR 1.006, 95% CI: 1.000; 1.014) and EAT attenuation (OR 1.011, 95% CI: 0.999; 1.024) remained in the model as risk factors for ARDS/death with a trend of statistical significance (Table 3).

### Discussion

The objective of this retrospective study was to identify biochemical parameters and CT characteristics associated with ARDS or death Covid-related. The need to identify early clinical markers of covid severity is compelling.

Obesity has been identified as risk factor for hypoventilation syndrome in intensive care unit (ICU) patients [18] and for respiratory failure in patients with ARDS [19].

Obesity is also associated with chronic inflammation and visceral adipose tissue is able of secreting inflammatory mediators such as IL-6, TNF, INF gamma, IL1 beta [20–22]. Moreover, in patients with obesity and diabetes, the expression of Angiotensin-converting enzyme 2 (ACE2), the functional receptor for Sars-CoV-2, is upregulated in adipocytes and turns adipose tissue into a potential target and viral reservoir. This may explain why the excess of VAT and diabetes are potential empowering factors for Covid-19 infection [23].




**Table 2** Correlation matrix between investigated variables

	Age	EAT volume	Glycemia	BMI	HDL	Gamma GT	AST	ALT	uricaemia	P/F ratio	fibrinogen	PCR	Waist circumference
Age	1.00												
EAT volume	0.31 <sup>a</sup>	1.00											
Glycemia	0.17 <sup>a</sup>	0.28 <sup>a</sup>	1.00										
BMI	0.09	0.47 <sup>a</sup>	0.17	1.00									
HDL	-0.08	-0.27 <sup>b</sup>	-0.22	-0.22 <sup>a</sup>	1.00								
Gamma GT	-0.07	0.33 <sup>a</sup>	0.25 <sup>a</sup>	0.33 <sup>a</sup>	-0.30 <sup>a</sup>	1.00							
AST	-0.065	0.14	0.17 <sup>a</sup>	0.24 <sup>a</sup>	-0.20	0.556 <sup>a</sup>	1.00						
ALT	-0.22 <sup>a</sup>	0.15 <sup>b</sup>	0.21 <sup>a</sup>	0.41 <sup>a</sup>	-0.13	0.66 <sup>a</sup>	0.72 <sup>a</sup>	1.00					
uricaemia	0.04	0.36 <sup>a</sup>	0.19	0.37 <sup>a</sup>	-0.18	0.30 <sup>a</sup>	0.33 <sup>a</sup>	0.11	1.00				
P/F ratio	-0.40 <sup>a</sup>	-0.25 <sup>a</sup>	-0.11	-0.33	0.32 <sup>a</sup>	-0.24 <sup>b</sup>	-0.15	-0.16	-0.08	1.00			
Fibrinogen	0.10	0.16 <sup>b</sup>	0.29 <sup>a</sup>	0.00	-0.14	0.29 <sup>a</sup>	0.312 <sup>a</sup>	0.29 <sup>a</sup>	-0.07	-0.01	1.00		
PCR	0.23 <sup>a</sup>	0.30 <sup>a</sup>	0.20 <sup>a</sup>	0.23 <sup>b</sup>	-0.42 <sup>a</sup>	0.41 <sup>a</sup>	0.452 <sup>a</sup>	0.26 <sup>a</sup>	0.13	-0.50 <sup>a</sup>	0.58 <sup>b</sup>	1.00	
Waist circumference	0.17 <sup>a</sup>	0.71 <sup>a</sup>	0.28 <sup>a</sup>	0.47 <sup>a</sup>	-0.23	0.32 <sup>a</sup>	0.15 <sup>b</sup>	0.17 <sup>a</sup>	0.39 <sup>a</sup>	-0.20	0.10	0.18	1.00

<sup>a</sup>Correlation is significant at the 0.01 level

<sup>b</sup>Correlation is significant at the 0.05 level

**Fig. 2** Correlation between EAT and Glycemia, P/F ratio at baseline, P/F nadir, PCR and Fibrinogen



**Table 3** Odds ratio (OR) of risk factors for developing ARDS or death at univariate and multivariate analysis

Variable	Univariate			Multivariable		
	OR	95% CI	p-value	OR	95% CI	p-value
Glycemia (mg/dL)	1.009	1.003–1.017	0.0122	1.006	1.000–1.014	0.0904
Age (years)	1.035	1.014–1.058	0.00108	1.025	1.003–1.049	0.0291
EAT density HU	1.004	0.994–1.015	0.403	1.011	0.999–1.024	0.0875
Gender F vs. M	0.730	0.402–1.321	0.299	–	–	–
EAT volume (cm <sup>3</sup> )	1.011	1.004–1.018	0.00218	1.009	1.002–1.018	0.0207
Waist circumference	1.024	1.004–1.044	0.0179	–	–	–

Some reports showed as CT-based quantification of VAT and upper abdominal circumference in routine chest CTs were associated to worse clinical outcome in patients with Sars-CoV-2 infection and as EAT closely correlated with

abdominal visceral adiposity and metabolic risk factors [24, 25].

Some authors have investigated the association between EAT and Covid-19 severity showing how epicardial fat

measured in terms of thickness at the level of the right coronary artery origin on the axial plane [7, 24] was similar among the groups of COVID-19 severity.

Other authors, using a fully automated, three-dimensional measurement of epicardial fat, which gives a better estimate of visceral deposits, have shown that EAT volume and attenuation were associated with the quantitative burden of Covid-19 pneumonia and that both parameters independently predicted clinical deterioration or death [8, 26].

In our study, using a semi-automatic three-dimensional adipose tissue volume quantification system, significantly higher VAT and, in particular, EAT volume were observed in the ARDS/death group and that EAT volume was an independent risk factor for negative outcome. Furthermore, it was interesting to note that although waist circumference is a proven cardiovascular risk factor and a strong marker of visceral adiposity and chronic inflammation, in our model, EAT remains as independent risk factor for ARDS/death compared to waist circumference. This finding suggests the usefulness and importance of performing radiological assessment of EAT in patients with Covid-19 undergoing chest CT. It was also interesting to note that the volume of EAT showed a progressive increase in parallel with the degree of ARDS (mild, moderate and severe). Indeed, not only the *P/F* at baseline, but also the nadir *P/F* (used to define the severity of ARDS) was positively correlated with EAT. The lack of difference in EAT attenuation between the two groups and among patients with different degrees of ARDS, could be probably explained by the attenuation calculated exclusively on a ROI of 6 mm. The absence of significant differences in VAT/SAT, on the other hand, could depend on the body segment studied by the CT. In fact, the thoracic SAT is an unreliable parameter of subcutaneous adiposity, since the maximum expression of the individual's subcutaneous adipose tissue is given by the SAT calculated at the level of the hips. The role of EAT as a viral reservoir and cytokine storm amplification site, could explain not only a worsening of lung function, but also the clinical deterioration up to multiorgan failure and death, through a direct/paracrine and indirect/systemic effect [26–29]. Interestingly, our study showed that EAT volume correlated, albeit weakly, with metabolic parameters, in particular with blood glucose. We found that fasting glucose was higher in the ARDS/death group and that fasting glucose at admission, had a trend as independent risk factor for ARDS or death. The fact that blood glucose was maintained within the multivariate model without being rejected indicates an important role in the onset of outcome, even if this data could be confirmed by increasing the sample size. This was in line with previous reports highlighting that admission hyperglycemia was a predictor of radiographic findings of ARDS [14] and that not only diabetes, as known, but also

infection-related hyperglycemia at admission were associated with an increased risk of adverse outcomes among patients with Covid-19 [30]. Further studies are needed to evaluate both the role of tight glycemic control in the outcome of Covid-19 pneumonia and the possibility of modifying EAT with target therapies to prevent the outbreak of the immune response. Our study has some limitations. First, the nature of this study was retrospective and only selected biochemical and clinical parameters were available; furthermore, the sample size was not previously planned for the state of emergency for which consecutive data were collected however about 229 patients guarantee to observe an ARDS or death incidence rate of 55% with an error margin of 6.5% and a confidence level of 95%. Second, the absence of BMI in about half of the population, due to the critical health and isolation conditions that prevented the physical examination of the patients, didn't allow to include this obesity measure in our multivariable model. Third, we didn't have the possibility of applying cardio-synchronization software to the CT acquisition. Fourth, the epicardial fat attenuation was calculated on a 6 mm ROI which did not allow an average estimate of the whole EAT attenuation. Some strengths should also be emphasized. First, our sample size was larger than in other studies. Second, the same decision-making protocol for hospitalization and treatment for all patients made the sample homogeneous in the severity of COVID-19 pneumonia or in hospital outcomes. Third, chest CT indications and acquisition protocols were standardized. Fourth, the semiautomatic quantification of visceral and epicardial fat volume and the positioning of the ROI for the estimation of tissue attenuation were performed by the same operator. This study is a confirmation of previous studies that investigated the association of epicardial adipose tissue with the outcomes of Covid-19, but unlike most studies in the literature, we had the opportunity to obtain a 3D quantification of epicardial fat. The interesting fact that emerges from this preliminary study is instead represented by the association between glycaemia at the time of admission and epicardial fat and that hyperglycemia, even mild and found also in non-diabetic patients, at the time of admission would seem to be involved in the development of complications from Covid-19. In conclusion, we found that EAT was correlated with inflammatory markers, as C-reactive protein and fibrinogen and fasting blood glucose. Our findings suggest that hyperglycemia in hospitalized patients should be adequately treated in patients with or without diabetes and that both blood glucose and EAT, as indirect parameters of inflammation and modifiable targets, could be involved in the development of Sars-CoV2-related complications and therefore included in the initial evaluation of patients admitted for Covid-19 pneumonia. Certainly, prospective studies with a higher sample size are needed to investigate

the predictive role of both hyperglycemia and epicardial fat that this preliminary observational analysis would seem to suggest.

**Acknowledgements** The authors wish to thank all the people who contributed to the study, to the interpretation of results and to the writing of the manuscript. All authors approved the final version of the article, including the authorship list.

**Funding** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Compliance with ethical standards

**Conflict of interest** The authors declare no competing interests.

**Ethical approval** All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

1. G. Guarisco, F. Leonetti, Covid-19 and diabetes: when a pandemic cross another pandemic. *Eat Weight Disord.* (2020). <https://doi.org/10.1007/s40519-020-00958-9>.
2. J. Lighter, M. Phillips, S. Hochman, S. Sterling, D. Johnson, F. Francois, A. Stachel, Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. *Clin. Infect. Dis.* **71**(15 Jul), 896–897 (2020). <https://doi.org/10.1093/cid/ciaa415>.
3. M. Deng, Y. Qi, L. Deng, H. Wang, Y. Xu, Z. Li, Z. Meng, J. Tang, Z. Dai, Obesity as a potential predictor of disease severity in young COVID-19 patients: a retrospective study. *Obesity* **28**(10 Oct), 1815–1825 (2020). <https://doi.org/10.1002/oby.22943>.
4. A.E. Malavazos, M.M. Corsi Romanelli, F. Bandera, G. Iacobellis, Targeting the adipose tissue in COVID-19. *Obesity* **28**(7 Jul), 1178–1179 (2020). <https://doi.org/10.1002/oby.22844>.
5. G. Iacobellis, Epicardial adipose tissue in endocrine and metabolic diseases. *Endocrine* **46**(1 May), 8–15 (2014). <https://doi.org/10.1007/s12020-013-0099-4>.
6. A.E. Malavazos, J.J. Goldberger, G. Iacobellis, Does epicardial fat contribute to COVID-19 myocardial inflammation? *Eur. Heart J.* **41**(24 Jun), 2333 (2020). <https://doi.org/10.1093/eurheartj/ehaa471>.
7. G. Iacobellis, F. Secchi, G. Capitanio, S. Basilico, S. Schiaffino, S. Boveri, F. Sardanelli, M.M. Corsi Romanelli, A.E. Malavazos, Epicardial fat inflammation in severe COVID-19. *Obesity* **28**(12 Dec), 2260–2262 (2020). <https://doi.org/10.1002/oby.23019>.
8. K. Grodecki, A. Lin, A. Razipour, S. Cadet, P.A. McElhinney, C. Chan, B.D. Pressman, P. Julien, P. Maurovich-Horvat, N. Gai-bazzi, U. Thakur, E. Mancini, C. Agalbato, R. Menè, G. Parati, F. Cernigliaro, N. Nerlekar, C. Tortlasco, G. Pontone, P.J. Slomka, D. Dey, Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19. *Metabolism* **115**(Feb), 154436 (2021). <https://doi.org/10.1016/j.meta.2020.154436>.
9. D. Caruso, M. Zerunian, M. Polici, F. Pucciarelli, T. Polidori, C. Rucci, G. Guido, B. Bracci, C. De Dominicis, A. Laghi, Chest CT features of COVID-19 in Rome, Italy. *Radiology* **296**(2 Aug), E79–E85 (2020). <https://doi.org/10.1148/radiol.2020201237>.
10. G. Iacobellis, A.E. Malavazos, T. Ferreira, COVID-19 rise in younger adults with obesity: visceral adiposity can predict the risk. *Obesity* **28**(10 Oct), 1795 (2020). <https://doi.org/10.1002/oby.22951>.
11. Y. Li, L. Xia, Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. *Am. J. Roentgenol.* **214**(6 Jun), 1280–1286 (2020). <https://doi.org/10.2214/AJR.20.22954>.
12. T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, L. Xia, Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology* **296**(2 Aug), E32–E40 (2020). <https://doi.org/10.1148/radiol.2020200642>.
13. F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y. Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen, B. Cao, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**(10229 Mar), 1054–1062 (2020). [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
14. G. Iacobellis, C.A. Penaherrera, L.E. Bermudez, E. Bernal Miz-rachi, Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. *Diabetes Res. Clin. Pract.* **164**(Jun), 108185 (2020). <https://doi.org/10.1016/j.diabres.2020.108185>.
15. G. Iacobellis, F. Assael, M.C. Ribaldo, A. Zappaterreno, G. Alessi, U. Di Mario, F. Leonetti, Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. *Obes. Res.* **11**(2 Feb), 304–310 (2003). <https://doi.org/10.1038/oby.2003.45>.
16. G. Iacobellis, F. Leonetti, U. Di Mario, Images in cardiology: massive epicardial adipose tissue indicating severe visceral obesity. *Clin. Cardiol.* **26**(5 May), 237 (2003). <https://doi.org/10.1002/clc.4960260508>.
17. ARDS Definition Task Force, V.M. Ranieri, G.D. Rubenfeld et al. Acute respiratory distress syndrome: The Berlin definition. *J. Am. Med. Assoc.* **307**, 2526–2533 (2012). <https://doi.org/10.1001/jama.2012.5669>.
18. P.E. Marik, C. Chen, The clinical characteristics and hospital and post-hospital survival of patients with the obesity hypoventilation syndrome: analysis of a large cohort. *Obes. Sci. Pract.* **2**(1), 40–47 (2016)
19. M.N. Gong, E.K. Bajwa, B.T. Thompson, D.C. Christiani, Body mass index is associated with the development of acute respiratory distress syndrome. *Thorax* **65**(1), 44–50 (2010). <https://doi.org/10.1136/thx.2009.117572>
20. M. Watanabe, R. Risi, D. Tuccinardi, C.J. Baquero, S. Manfrini, L. Gnessi, Obesity and SARS-CoV-2: a population to safeguard. *Diabetes Metabol. Res. Rev.* **36**, e3325 (2020).
21. A. Chait, L.J. den Hartigh, Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. *Front. Cardiovasc. Med.* **7**, 22 (2020)
22. D.F. Quail, A.J. Dannenberg, The obese adipose tissue micro-environment in cancer development and progression. *Nat. Rev. Endocrinol.* **15**(3 Mar), 139–154 (2019). <https://doi.org/10.1038/s41574-018-0126-x>
23. I.L. Kruglikov, P.E. Scherer The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. *Obesity.* (2020). <https://doi.org/10.1002/oby.22856>
24. M. Watanabe, D. Caruso, D. Tuccinardi, R. Risi, M. Zerunian, M. Polici, et al. Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19. *Metabolism.* **111**, 154319 (2020).
25. G.A. Rosito, J.M. Massaro, U. Hoffmann, F.L. Ruberg, A.A. Mahabadi, R.S. Vasan et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham heart study. *Circulation* **117**, 605–613 (2008)
26. G. Iacobellis, A.A. Mahabadi, Is epicardial fat attenuation a novel marker of coronary inflammation? *Atherosclerosis* **284**, 212–213 (2019)



27. P.M. Ryan, N.M. Caplice, Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? *Obesity* **28**, 1191–1194 (2020)
28. J.B. Moore, C.H. June, Cytokine release syndrome in severe COVID-19. *Science* **368**, 473 (2020)
29. G. Iacobellis, D. Corradi, A.M. Sharma, Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. *Nat. Clin. Pract. Cardiovasc. Med.* **2**, 536–543 (2005)
30. J. Zhang, W. Kong, P. Xia, Y. Xu, L. Li, Q. Li, L. Yang, Q. Wei, H. Wang, H. Li, J. Zheng, H. Sun, W. Xia, G. Liu, X. Zhong, K. Qiu, Y. Li, H. Wang, Y. Wang, X. Song, H. Liu, S. Xiong, Y. Liu, Z. Cui, Y. Hu, L. Chen, A. Pan, T. Zeng, Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019. *Front. Endocrinol.* **11**(Jul), 525 (2020). <https://doi.org/10.3389/fendo.2020.00525>.